[go: up one dir, main page]

AR077695A1 - Derivados de pirimidina como inhibidores del factor ixa - Google Patents

Derivados de pirimidina como inhibidores del factor ixa

Info

Publication number
AR077695A1
AR077695A1 ARP100102849A ARP100102849A AR077695A1 AR 077695 A1 AR077695 A1 AR 077695A1 AR P100102849 A ARP100102849 A AR P100102849A AR P100102849 A ARP100102849 A AR P100102849A AR 077695 A1 AR077695 A1 AR 077695A1
Authority
AR
Argentina
Prior art keywords
heterocyclyl
heteroaryl
aryl
substituents
cycloalkyl
Prior art date
Application number
ARP100102849A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR077695A1 publication Critical patent/AR077695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

También se divulgan composiciones farmacéuticas que comprenden dichos compuestos y métodos para usar dichos compuestos para tratar o prevenir un trastorno tromboembolico. Reivindicacion 1: Un compuesto de formula (1) o una de sus sales o solvatos farmacéuticamente aceptable, donde X1 se selecciona del grupo que consiste en un enlace covalente, -S- y -O-; R1 se selecciona del grupo que consiste en halo, cicloalquilo, heterociclilo, arilo y heteroarilo, donde cuando cada uno de dicho cicloalquilo, heterociclilo, arilo y heteroarilo tiene sustituyentes en átomos de carbono adyacentes, dichos sustituyentes se pueden tomar opcionalmente junto con los átomos de carbono a los que están unidos para formar un primer cicloalquilo, heterociclilo, arilo o heteroarilo de cinco o seis miembros, donde cuando dicho primer cicloalquilo, heterociclilo, arilo o heteroarilo de cinco o seis miembros tiene sustituyentes en átomos de carbono adyacentes, dichos sustituyentes se pueden tomar opcionalmente junto con los átomos de carbono a los que están unidos para formar un segundo cicloalquilo, heterociclilo, arilo o heteroarilo de cinco o seis miembros; X2 se selecciona del grupo que consiste en un enlace covalente, y -O-; R2 se selecciona del grupo que consiste en H, halogeno y alquilo, con la condicion de que cuando X2 es un enlace covalente, R2 es halogeno; X3 se selecciona del grupo que consiste en un enlace covalente, -N(R)- y -O-; R es H o alquilo; R3 se selecciona del grupo que consiste en halo, alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, donde cuando cada uno de dicho cicloalquilo, heterociclilo, arilo y heteroarilo tiene sustituyentes en átomos de carbono adyacentes, dichos sustituyentes se pueden tomar opcionalmente junto con el átomo de carbono al que están unidos para formar un primer cicloalquilo, heterociclilo, arilo o heteroarilo de cinco o seis miembros, donde cuando dicho cicloalquilo, heterociclilo, arilo o heteroarilo de cinco o seis miembros tiene sustituyentes en átomos de carbono adyacentes, dichos sustituyentes se pueden tomar opcionalmente junto con los átomos de carbono a los cuales están unidos para formar un segundo cicloalquilo, heterociclilo, arilo o heteroarilo de cinco o seis miembros; y R4 se selecciona del grupo que consiste en alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo; con la condicion de que cuando X1 y X3 son ambos -O-, entonces -X2-R2 es distinto de -halo.
ARP100102849A 2009-08-04 2010-08-03 Derivados de pirimidina como inhibidores del factor ixa AR077695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23107009P 2009-08-04 2009-08-04

Publications (1)

Publication Number Publication Date
AR077695A1 true AR077695A1 (es) 2011-09-14

Family

ID=42735270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102849A AR077695A1 (es) 2009-08-04 2010-08-03 Derivados de pirimidina como inhibidores del factor ixa

Country Status (5)

Country Link
US (1) US8609676B2 (es)
EP (1) EP2462123B1 (es)
AR (1) AR077695A1 (es)
TW (1) TWI393716B (es)
WO (1) WO2011017296A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2013009527A2 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Factor ixa inhibitors
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
JP6026544B2 (ja) 2011-09-27 2016-11-16 ノバルティス アーゲー 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
HRP20170784T8 (hr) 2011-10-14 2018-05-18 Bristol-Myers Squibb Company Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US8980916B2 (en) 2011-10-27 2015-03-17 Merck Sharp & Dohme Corp. Factor IXa inhibitors
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
HRP20180465T1 (hr) 2012-10-12 2018-05-04 Bristol-Myers Squibb Company Kristalni oblici inhibitora faktora xia
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
HK1213251A1 (zh) 2013-03-14 2016-06-30 Novartis Ag 作为突变idh抑制剂的3-嘧啶-4-基-恶唑烷-2-酮化合物
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
NO2760821T3 (es) 2014-01-31 2018-03-10
CN104003942A (zh) * 2014-03-10 2014-08-27 常熟市南湖实业化工有限公司 避免串温现象产生的5-甲氧基-4,6-二氯嘧啶制备方法
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EA034440B1 (ru) 2015-10-29 2020-02-07 Эффектор Терапьютикс, Инк. СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
EP3368530A1 (en) 2015-10-29 2018-09-05 Effector Therapeutics Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
MX2018006479A (es) 2015-11-25 2019-01-28 Academisch Ziekenhuis Leiden Serinas proteasas recombinantes.
TWI762579B (zh) 2017-02-14 2022-05-01 美商伊凡克特治療公司 六氫吡啶經取代之ＭｎＫ抑制劑及其相關方法
JP2022505846A (ja) 2018-10-24 2022-01-14 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ阻害剤の結晶形態

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
MY130642A (en) 2000-06-15 2007-07-31 Schering Corp Nor-seco himbacine derivatives useful as thrombin receptor antagonists
MXPA04003610A (es) 2001-10-18 2004-07-27 Schering Corp Analogos de himbacina como antagonistas del receptor de trombina.
ATE378330T1 (de) 2002-04-16 2007-11-15 Schering Corp Trizyklische thrombin rezeptor antagonisten
DE10234875A1 (de) * 2002-07-25 2004-02-05 Bayer Cropscience Gmbh 4-Trifluormethylpyrazolyl substituierte Pyridine und Pyrimidine
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
US7168775B2 (en) 2003-09-03 2007-01-30 Canon Kabushiki Kaisha Recording apparatus
JP2007510706A (ja) * 2003-11-10 2007-04-26 メルク シャープ エンド ドーム リミテッド 痛みを治療するためのバニロイド−１受容体アンタゴニストとしての、置換された含窒素六員アミノ複素環
JP2005232081A (ja) * 2004-02-19 2005-09-02 Bayer Cropscience Ag ベンジルピリミジン誘導体の農園芸用殺菌剤としての利用
DE602006011752D1 (de) 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
EP1968956A2 (en) * 2005-12-22 2008-09-17 Icagen, Inc. Calcium channel antagonists
US7705018B2 (en) * 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
NZ585284A (en) * 2007-10-16 2011-03-31 Daiichi Sankyo Co Ltd Pyrimidyl indoline compounds with hypoglycaemic effect useful in the treatment of diabetes related diseases and adiposity
JP5600063B2 (ja) * 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
AU2008317057B8 (en) * 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
AU2009330208A1 (en) * 2008-12-23 2011-08-04 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
AR076024A1 (es) * 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos

Also Published As

Publication number Publication date
EP2462123A1 (en) 2012-06-13
WO2011017296A1 (en) 2011-02-10
US20120136016A1 (en) 2012-05-31
TW201118080A (en) 2011-06-01
US8609676B2 (en) 2013-12-17
EP2462123B1 (en) 2013-10-02
TWI393716B (zh) 2013-04-21

Similar Documents

Publication Publication Date Title
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
CO6561783A2 (es) Inhibidores del virus flaviviridae
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
MX2016015641A (es) Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina.
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
CR20170066A (es) Compuestos aminopirimidinilo como inhibidires de jak
MX2016012984A (es) Derivados indol para uso en medicina.
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR065280A1 (es) Agentes antiparasitarios
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR097866A1 (es) Derivados de 4-azaindol
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR078270A1 (es) Inhibidores de jak (quinasas janus)
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR095351A1 (es) Inhibidores de histona desacetilasa (hdac)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal